Very small tumors are usually under-represented in clinical trials, e.g. in the TAILORx study only 13% of patients had tumors 1cm or smaller (tumor 0.5 > were excluded) [4] and in the NSABP B-20 trial (excluding HER2 positive by RT-PCR) only 14.9% had such tumors [3]. This evidence concerns the gene ERBB2 and neoplasm.